

Interests Register

Cannabis-based medicinal products Advisory Committee

Publication Date: 21/10/2019

| Name | Role with NICE | Type of interest | Description of interest | Relevant dates | | | Comments |
|---------------|--|---|---|----------------|-------------------|-----------------|---|
| | | | | Interest arose | Interest declared | Interest ceased | |
| Steve Pilling | Chair | None | NA | NA | NA | NA | No action |
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Direct non-financial and indirect financial | Education session presented at the Clinical Pharmacy Congress. About Parkinson's disease and its management. Expenses paid but honorarium donated to charity. | Apr 2018 | Oct 2018 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Direct non-financial and indirect financial | Attended an advisory board meeting to review new migraine drug (Novartis) – Expenses received but honorarium donated to charity. | Jun 2018 | Oct 2018 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|---------------|---|--|--|----------|----------|--|---|
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Direct non- financial and indirect financial | Attended an advisory board meeting review new injectable Parkinson's drug (Ever Pharma). Expenses paid but honorarium donated to charity. | Oct 2018 | Oct 2018 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Indirect financial | Founder and Chair of PDSPN (Parkinson's Disease Specialist Pharmacy Network). Steering committee meetings sponsored (room hire and refreshments) by Profile Pharma (the company does not manufacture any Cannabis-derived products), with no input from Pharma company regarding content of meeting. The meeting is about Parkinson's disease education, cannabis- based products will not be discussed. No direct payment. | Oct 2018 | Feb 2019 | | Declare and participate Cannabis-based products not covered |

| | | | | | | | |
|-------------------|---|--|--|--------|----------|--|---|
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Direct non-financial and indirect financial | Presented at an educational event, on Parkinson's disease. Event sponsored by Union Chimique Belge. Expenses paid but honorarium donated to charity. | Mar 19 | Apr 19 | | Declare and participate Cannabis-based products not covered |
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Indirect financial | Presented at the Clinical Pharmacy Congress in London about their role and Parkinson's disease management. Honorarium donated to charity. | Jun 19 | Jun 19 | | Declare and participate Cannabis-based products not covered |
| Janine Barnes | Committee member Neurology Specialist Pharmacist | Indirect financial | Presented at the Care of the Elderly conference, about Parkinson's disease management. Honorarium donated to charity. | Jun 19 | Jun 19 | | Declare and participate Cannabis-based products not covered |
| Brigitta Brandner | Committee member Consultant Anaesthetist | Direct non-financial personal and professional | Chair of SPIN (Specialists in Pain International Network) a charity for education and teaching in | 2013 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|-------------------|--|--|---|----------|----------|----|-------------------------|
| | | | multidisciplinary pain management. | | | | |
| Brigitta Brandner | Committee member Consultant Anaesthetist | Direct non-financial personal and professional | Member of Drug Science (independent scientific committee on drugs). | 2018 | Jan 2019 | | Declare and participate |
| Brigitta Brandner | Committee member Consultant Anaesthetist | Direct non-financial personal and professional | Provided a teaching session to students within employer organisation on cannabis and cannabinoids | May 2019 | May 2019 | | Declare and participate |
| Luke Brooker | Committee member Lay member | None | None | NA | NA | NA | NA |
| Margred Capel | Committee member Consultant in Palliative Medicines | Direct non-financial personal and professional | Member of the professional standards committee for the Association of Palliative Medicine. | 2010 | Oct 2018 | | Declare and participate |
| Margred Capel | Committee member Consultant in Palliative Medicines | Direct non-financial personal and professional | Training programme director for palliative medicine registrars in Wales. | Jan 2019 | Jan 2019 | | Declare and participate |

| | | | | | | | |
|-------------------------|---------------|--|---|------|--|--|---|
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Investigator on Cannabidiol RCTs and epilepsy studies, sponsored by GW Pharma. Remuneration to department | 2014 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any comments made by the peer reviewer. |
| Helen Cross May 2019 | Peer reviewer | Direct non-financial personal and professional | Coordinated use of CBD for children and young people with Dravet and Lennox Gastaut syndromes | 2018 | | | Declare and participate |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Investigator on fenfluramine trials, for the treatment of Dravet syndrome, sponsored by Zogenix. Remuneration to department | 2016 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any |

| | | | | | | | |
|-------------------------|---------------|--------------------|---|------|--|--|---|
| | | | | | | | comments made by the peer reviewer. |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Speaker at symposia, on, on the ketogenic diet in childhood epilepsy (on 1 or 2 occasions.) Sponsored by Nutricia Remuneration to department | 2016 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any comments made by the peer reviewer. |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Speaker at symposia, on Clinical trial methodology in rare epilepsies (on 1 or 2 occasions.) Sponsored by Zogenix. Remuneration to department | 2016 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any |

| | | | | | | | |
|-------------------------|---------------|--------------------|---|------|--|--|---|
| | | | | | | | comments made by the peer reviewer. |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Investigator for pilot study of, tolerability of a nutritional product in children with epilepsy, Vitaflo. Remuneration to department | 2014 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any comments made by the peer reviewer. |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Organised annual meeting on behaviour and epilepsy, educational grant from Sanofi | 2014 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any |

| | | | | | | | |
|-------------------------|---------------|--------------------|--|------|--|--|--|
| | | | | | | | comments made by the peer reviewer |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | GW Pharma advisory board on CBD in Dravet and Lennox Gastaut syndromes, remuneration to department | 2018 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any comments made by the peer reviewer |
| Helen Cross May 2019 | Peer reviewer | Indirect financial | Investigator CDKL5 study, funded by Marinus | 2019 | | | Declare and participate The role is peer review only. No attendance at committee meetings or involvement in drafting recommendations. The committee will take into consideration any potential conflicts when discussing any |

| | | | | | | | |
|-------------------------|--|--|---|----------|----------|--|--|
| | | | | | | | comments made by the peer reviewer |
| Helen Cross May 2019 | Peer reviewer | Direct non-financial personal and professional | Interview with the BBC (written), in May 2019, regarding the effect of cannabis-based medicine, and epilepsy | May 2019 | | | Declare and participate |
| Danielle Davis | Committee member Lay member | Direct non-financial personal and professional | Interview with the BBC (written), in May 2019, regarding the effect of cannabis-based medicine, on her daughters medical condition (Dravet syndrome) | May 2019 | | | Declare and participate |
| Lisa Dolley | Committee member Lay member | Direct financial | Member of the NIHR Research for Patient Benefit group, south west (3meetings a year). Paid an honorarium, and expenses. | May 18 | Jan 19 | | Declare and participate Research on Cannabis-based products not covered. |
| Rachel Farrell | Committee member Consultant Neurologist | Indirect financial and direct non-financial | Chief Investigator for a company Canbex (University of London Collage Hospitals, business). With the aim to develop an agent to interact with the | Jun 2015 | Oct 2018 | | Declare and participate Potentially novel agent will not be covered within the scope of the guideline |

| | | | | | | | |
|----------------|--|------------------|--|----------|----------|--|---|
| | | | endocannabinoid system, to treat spasticity in Multiple Sclerosis. The fees were paid to University of London Collage Hospitals, Investigator account. | | | | |
| Rachel Farrell | Committee member Consultant Neurologist | Direct financial | Presented an educational talk on MS related to all aspects of spasticity in March 2018. Included published data and Trust observational data. The presentation did include THC and CBD, regarding ITB and Nabiximols. Honorarium paid by Teva. | Mar 2018 | Oct 2018 | | Declare and participate Cannabis-based products aspect of the presentation was purely educational and did not promote any treatment option. Presentation was written by committee member with no input from commercial organisation. |
| Rachel Farrell | Committee member Consultant Neurologist | Direct financial | Attended an Advisory board (Greenwich Biosciences Ltd), in Washington July 2018, to speak about MS spasticity management strategies and service provision in the UK. Honorarium and travel expenses paid. | Jun 2018 | Oct 2018 | | Declare and participate Cannabis-based products were not covered |

| | | | | | | | |
|----------------|---|--|--|----------|----------|----|---|
| Rachel Farrell | Committee member Consultant Neurologist | Direct financial | Speaker at MS nursing educational conference CHARMS Feb 2019. Presented, management of spasticity in people with MS. Covering all licensed treatments for spasticity in MS, including cannabis based products. Honorarium paid by MERCK (they do not produce any of the treatments mentioned in the talk) | Feb 2019 | Feb 2019 | | Declare and participate Cannabis-based products aspect of the presentation was purely educational and did not promote any treatment option |
| Rachel Farrell | Committee member Consultant Neurologist | Direct non-financial personal and professional | Medical advisory committee member for the MS Society, to provide advice on treatments, devices, rehabilitation and management of MS. | Mar 2019 | Mar 2019 | | Declare and participate Will not include cannabis-based products |
| Rachel Farrell | Committee member Consultant Neurologist | Direct financial | Presentation on MS, and walking impairment, for Merck on the 4th April 2019. An honorarium was paid. | Apr 2019 | Apr 2019 | | Declare and participate Cannabis-based products were not covered |
| Tom Freeman | Expert Witness | None | None | NA | NA | NA | April 2019 |

| | | | | | | | |
|-------------------|---|--|--|----------|----------|--|---|
| Vivienne Harpwood | Committee member Medicine, Ethics and Law Specialist | Direct financial | Chair of Powys teaching health board. | 2014 | Nov 2018 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Vivienne Harpwood | Committee member Medicine, Ethics and Law Specialist | Direct financial | Chair of the Welsh health specialised services Committee, dealing with independent patient funding requests. | 2017 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Vivienne Harpwood | Committee member Medicine, Ethics and Law Specialist | Direct financial | Author of a distance learning course, on consent to treatment. Payment is received, and provided by EIDO Healthcare. | 2015 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline |
| Vivienne Harpwood | Committee member Medicine, Ethics and Law Specialist | Direct non-financial personal and professional | Chair of Wales NHS confederation | Feb 2019 | Mar 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Soraya Mayet | Committee member Consultant Psychiatrist | Direct non-financial personal and professional | Royal College Psychiatrists Addictions Faculty Executive, committee member. | 2016 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|-----------------|--|---|--|----------|----------|--|---|
| Soraya Mayet | Committee member Consultant Psychiatrist | Direct non-financial personal and professional | Royal College Psychiatrists patient safety working group member. | 2014 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Soraya Mayet | Committee member Consultant Psychiatrist | Direct financial | Teaches a yearly session once on addictions, for the Royal College of GPs. | Jul 2017 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Soraya Mayet | Committee member Consultant Psychiatrist | Direct financial (expenses only) | Co-opted member of the NICE Chronic pain: assessment and management committee. | Jan 2018 | Jan 2019 | | Declare and participate Cannabis-based products not covered |
| Renee McCulloch | Committee member Consultant in Paediatric Palliative Medicine | Direct non-financial personal and professional | Chair of Royal College of Paediatrics and Child Health palliative care. | Jan 2017 | Jan 2019 | | Declare and participate Not specific to any topic covered in the scope of the guideline. |
| Renee McCulloch | Committee member Consultant in Paediatric Palliative Medicine | Direct non-financial personal and professional | Approximately 3 teaching sessions per year, on Children's palliative medicine for the Association of Paediatric Medicine | 2007 | Jan 2019 | | Declare and participate Cannabis-based products not covered |

| | | | | | | | |
|-----------------|--|--|--|------|----------|--|---|
| Renee McCulloch | Committee member Consultant in Paediatric Palliative Medicine | Direct non-financial personal and professional | Approximately 1 teaching session every 2 years, on Children's palliative medicine for the Royal Society Medicine | | Jan 2019 | | Declare and participate Cannabis-based products not covered |
| Renee McCulloch | Committee member Consultant in Paediatric Palliative Medicine | Direct non-financial personal and professional | Teaching sessions (one week Jan 2018) on Children's palliative medicine for the Institute of Child Health | 2018 | Jan 2019 | | Declare and participate Cannabis-based products aspect of the presentation was purely educational and did not promote any treatment option |
| Renee McCulloch | Committee member Consultant in Paediatric Palliative Medicine | Direct financial (travel and accommodation only) | Speaker at European Association Palliative Care, May 2019 - The Role of Cannabinoids in the Care of Children with Life-Limiting Conditions and Life-Threatening Illnesses: Patient, Family, Clinician and Research perspectives' - no opinion provided | 2019 | Jan 2019 | | Declare and participate Cannabis-based products aspect of the presentation purely educational and does not promote any treatment option |
| Renee McCulloch | Committee member Consultant in Paediatric Palliative Medicine | Direct non-financial personal and professional | Teaching sessions on Children's palliative medicine for a number of NHS Trusts, on average 3 to 5 per year | 2017 | Jan 2019 | | Declare and participate Cannabis-based products was not covered |

| | | | | | | | |
|--------------------|---|--|--|----------|----------|----|--|
| Andrew McPartlin | Committee member Consultant Oncologist | None | NA | NA | NA | NA | No action |
| Claire McVey | Committee member Nurse Specialist | None | NA | NA | NA | NA | No action |
| Dermot Murphy | Committee member Consultant Paediatrician | Direct financial | Paid to give lectures in Russia regarding the use of antibody therapy in neuroblastoma by Eusa. | Nov 2017 | Oct 2018 | | Declare and participate Cannabis-based products was not covered |
| Dermot Murphy | Committee member Consultant Paediatrician | Direct financial (travel and accommodation only) | Travel and accommodation to attend European Neuroblastoma meetings by Eusa. | May 2016 | Oct 2018 | | Declare and participate Cannabis-based products was not covered |
| Finbar O'Callaghan | Committee member Paediatric Consultant Neurologist | Direct non-financial personal and professional | Assisted with the recruitment at Great Ormond Street in the GW Pharma trials of epidiolex (cannabidiol) in children with Dravet and Lennox-Gastaut syndrome. Not otherwise involved in the trails or publications. | | Jan 2019 | | Declare and participate |

| | | | | | | | |
|--------------------|---|--|---|----------|----------|----|--|
| Finbar O'Callaghan | Committee member Paediatric Consultant Neurologist | Direct non-financial personal and professional | President of the British Paediatric Neurology Association. | Jan 2019 | Jan 2019 | NA | Declare and participate |
| Finbar O'Callaghan | Committee member Paediatric Consultant Neurologist | Direct non-financial personal and professional | 19th March 2019, appeared in an ITV interview, medicinal cannabis and epilepsy, as president of the British Paediatric Neurology Association. | Mar 2019 | May 2019 | | Declare and participate |
| Finbar O'Callaghan | Committee member Paediatric Consultant Neurologist | Direct non-financial personal and professional | Appeared in a BBC news interview, medicinal cannabis and epilepsy, as president of the British Paediatric Neurology Association. | Mar 2019 | May 2019 | | Declare and participate Interview did not promote or dispute the use of cannabis-based products for medicinal use |
| Finbar O'Callaghan | Committee member Paediatric Consultant Neurologist | Direct non-financial personal and professional | Appeared in a channel news interview, medicinal cannabis and epilepsy, as president of the British Paediatric Neurology Association. | Mar 2019 | May 2019 | | Declare and participate Interview did not promote or dispute the use of cannabis-based products for medicinal use |

| | | | | | | | |
|------------------------------------|---|--|--|----------|----------|--|---|
| Finbar O'Callaghan | Committee member Paediatric Consultant Neurologist | Direct non-financial personal and professional | Expert witness parliament select committee, Tuesday 26 March, on epilepsy and cannabis | Mar 2019 | Mar 2019 | | Declare and participate Interview did not promote or dispute the use of cannabis-based products for medicinal use |
| David Spraggett From March 2019 | Committee member GP | Direct, financial | Full GP Partner in General Practice, Castle Medical Centre, Kenilworth | 1986 | Jan 2019 | | Declare and participate. Although the practice has experience of prescribing cannabis-based products via a Home Office licence the practice is not formally linked to any pharmacy dispensing cannabis-based products and does not promote expertise in the use of cannabis-based products |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.